Johnson & Johnson announced that the US Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with moderate-to-severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback